Cowen and Company’s Rocket Pharmaceuticals RCKT Stock Holding History

Cowen and Company’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,100,000	Closed	-$20.3M	–	242
2024 Q3	$20.3M	Hold	1,100,000	–	–	0.68%	22
2024 Q2	$23.7M	Hold	1,100,000	–	–	0.65%	23
2024 Q1	$29.6M	Hold	1,100,000	–	–	1.15%	14
2023 Q4	$33M	Hold	1,100,000	–	–	2.16%	10
2023 Q3	$22.5M	Hold	1,100,000	–	–	1.58%	15
2023 Q2	$21.9M	Hold	1,100,000	–	–	1.81%	13
2023 Q1	$18.8M	Hold	1,100,000	–	–	2.21%	12
2022 Q4	$21.5M	Buy	1,100,000 +100,412	+10%	+$1.85M	2.25%	15
2022 Q3	$16M	Sell	999,588 -412	-0%	-$6.43K	1.53%	21
2022 Q2	$13.8M	Hold	1,000,000	–	–	1.33%	24
2022 Q1	$15.9M	Hold	1,000,000	–	–	1.53%	17
2021 Q4	$21.8M	Hold	1,000,000	–	–	1.98%	12
2021 Q3	$29.9M	Hold	1,000,000	–	–	1.42%	16
2021 Q2	$44.3M	Buy	+1,000,000	New	+$43.4M	2.31%	9

Other funds holding RCKT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cowen and Company's RCKT Position: Q4 2024 in Review

Cowen and Company sold out of Rocket Pharmaceuticals (RCKT) in Q4 2024, closing a stake of 1,100,000 shares — an estimated $20.3M sold.

Cowen and Company first reported a position in RCKT in Q2 2021 and held it in 14 quarters. The position peaked at $44.3M in Q2 2021. 225 funds tracked by Wall St. Rank hold RCKT as of Q4 2024.

Cowen and Company reported no remaining Rocket Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Cowen and Company sold 1,100,000 Rocket Pharmaceuticals shares in Q4 2024, an estimated $20.3M.
Cowen and Company first reported a position in Rocket Pharmaceuticals in Q2 2021 and held it in 14 quarters.
Cowen and Company's Rocket Pharmaceuticals position peaked at $44.3M in Q2 2021.
225 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.